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Duloxetine is a balanced and potent serotonin and noradrenaline reuptake inhibitor (SNRI) and has adverse effects that are commonly 
associated with such drugs, including nausea, dry mouth, constipation, insomnia, and dizziness. Recently, duloxetine-induced liver injury 
has also been observed in patients with preexisting liver disease or chronic alcohol use. We investigated the effects of duloxetine in a healthy 
young adult with major depressive disorder (MDD) but no risk factors, and found that his total bilirubin level increased to 3.3 mg/dL 
and he developed jaundice after 5 months of duloxetine treatment. Discontinuation of duloxetine treatment saw his total bilirubin level 
decrease to 1.8 mg/dL. Thus, the administration of duloxetine might induce liver injury in a patient with MDD. However, the limitations 
of this single case report must be acknowledged. Although the cause of hepatic dysfunction in this case remains to be elucidated, clini-
cians should monitor liver function carefully after duloxetine treatment. Further investigations with a larger sample are needed.
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INTRODUCTION
Duloxetine, one of a series of serotonin and noradrenaline 
reuptake inhibitors (SNRIs), was released in Korea in 2009 as 
a treatment for major depressive disorder (MDD), generalized 
anxiety disorder (GAD), and diabetic peripheral neuropathic 
pain (DPNP). Duloxetine is a balanced and potent SNRI, 
and has adverse effects that are common to the other SNRIs, in-
cluding nausea, dry mouth, constipation, insomnia, and dizzi-
ness.
1 Duloxetine-induced liver injury has also recently been 
observed in patients with preexisting liver disease.
2 During the 
first 2 years after the release of duloxetine, 406 cases of events 
potentially relating to hepatic dysfunction were reported.
3 Thus, 
the information sheet provided with duloxetine is now re-
quired state that it should not be used in patients with any form 
of chronic liver disease or in those with chronic alcohol use.
2
We describe herein a case of jaundice in a patient with MDD 
who was medicated with duloxetine but had no risk factors. A 
MEDLINE search has revealed no other report related to hy-
perbilirubinemia alone induced by duloxetine, and thus this 
appears to be the first reported case thereof.
CASE
A 22-year-old Korean male visited our clinic in 2009 due to 
the onset of a major depressive episode. The presenting symp-
toms were depressed mood, avolition, idea of reference, insom-
nia, guilty feeling, and suicidal ideation. The last symptom re-
sulted in him being admitted to a closed psychiatric ward.
The patient had no medical history and no history of sub-
stance abuse; his laboratory tests were also normal. He was di-
agnosed with MDD. He was initially treated with mirtazapine 
at 15 mg, which was subsequently escalated to 45 mg. Howev-
er, the patient had only a partial response to this drug. As a re-
sult, an initial dose of 30 mg duloxetine was added to mirtazap-
ine, and subsequently escalated to 60 mg. The patient’s symp-
tomatology largely remitted after this combination treatment, 
and so he was discharged to day-clinic treatment. Just prior to 
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his discharge, laboratory tests were repeated, and all of them 
(including the liver function test) produced normal results; 
his total bilirubin was 1.0 mg/dL and alkaline phosphatase 
(ALP) was 88 U/L.
After discharge, the patient maintained the mirtazapine (45 
mg) and duloxetine (60 mg) combination therapy for 3 months. 
During this time he developed jaundice in his eyes. Liver func-
tion tests were repeated again, and although he did not com-
plain of any symptoms, his total bilirubin level had increased 
to 3.3 mg/dL, while other test results were within normal lim-
its (e.g., ALP 111 U/L). Duloxetine was discontinued immedi-
ately. At 1 month after discontinuation of duloxetine, the pa-
tient’s total bilirubin had decreased to 1.8 mg/dL, ALP remained 
normal at 109 U/L, and the jaundice had disappeared. 
DISCUSSION
Drug-induced liver injury (DILI) is one of the most common 
reasons for drug discontinuation,
4 and is the most common 
cause of acute liver failure.
5 DILI is most often mediated by an 
idiosyncratic process that has been divided into two parts: me-
tabolic and immune-mediated.
6,7 The pathology of DILI is di-
vided into hepatocellular, cholestatic, and mixed hepatocel-
lular-cholestatic injury, depending on the particular abnorma-
lity detected in the liver function test.
6-8 The US Food and Drug 
Administration (FDA) defines DILI as a persistent elevation 
of at least three times the upper limit of normal (ULN) in al-
anine transaminase (ALT) levels accompanied by jaundice 
(total bilirubin greater than or equal to twice the ULN).
7
Duloxetine was approved by the US FDA in 2004. Howev-
er, in late 2005, a “Dear Health Care Professional” letter was 
sent by Eli Lilly and Company. In this letter, the company men-
tioned that there had been some postmarketing reports of 
cholestatic jaundice and hepatitis in patients with chronic liver 
disease or cirrhosis receiving duloxetine. Thus, a note was add-
ed to the product labeling to the effect that duloxetine should 
not ordinarily be prescribed to patients with chronic alcohol 
use or where there was evidence of chronic liver disease.
2 Thus, 
individuals with preexisting chronic liver disease or those con-
suming significant amounts of alcohol may be at a greater risk 
of duloxetine-induced liver injury.
8
The hepatic dysfunction caused by duloxetine was first ob-
served during preclinical studies and in human clinical trials. 
Preclinical rodent and canine studies showed hepatic dysfunc-
tion consistent with microsomal enzyme induction, but no 
overt liver injury.
9 However, some clinical studies did find an 
association between liver injury and medication with dulox-
etine. It was reported that duloxetine treatment for DPNP was 
associated with a significant increase in ALP levels.
10 In partic-
ular, the high-dose group (duloxetine 60 mg twice daily) ex-
hibited a significant increase in γ-glutamyl transferase. It was 
also reported that duloxetine was associated with an elevation 
in aminotransferases to more than three times the ULN in 1% 
of patients. In patients with a normal baseline ALT, both ALT 
and aspartate transaminase values peaked at 8 weeks, ALP st-
eadily increased to a maximum value at 52 weeks, and mean 
total bilirubin levels remained unchanged.
11
In the one published case related to duloxetine-induced 
liver injury, hepatic failure occurred 6 weeks after dose escala-
tion from 30 to 60 mg daily.
12 Like our patient, that patient had 
received combination therapy of duloxetine and mirtazapine. 
Thus, it is unclear whether both agents were responsible for 
the hepatic failure or duloxetine alone. However, it has been 
pointed out that liver injury associated with mirtazapine is 
rare.
13 The situation in our case is clearer than in the previous 
one, because the discontinuation of duloxetine improved the 
jaundice and decreased the total bilirubin levels, in spite of 
persisting mirtazapine treatment. Thus, it is possible that du-
loxetine alone is responsible for hepatic dysfunction.
Our patient showed a unique pattern of duloxetine-induced 
hepatic dysfunction. First, he was a healthy young adult with 
no risk factors, such as preexisting liver disease or chronic al-
cohol use. Second, the total bilirubin level of our patient was 
3.3 mg/dL, while the results of other liver function tests were 
within normal limits. In particular, ALP related to cholestatic 
injury was also within the normal range, although it did incre-
ase slightly from 88 to 111 U/L. However, it should be noted 
that ALP steadily increased to a maximum value at week 52 
after duloxetine initiation.
11
It may be concluded that the administration of duloxetine 
can induce liver injury in a patient with MDD. However, the 
limitations of this single case report must be acknowledged. 
Although the mechanism underlying the observed hepatic 
dysfunction in this case remains unclear, clinicians should mo-
nitor liver function carefully after duloxetine treatment. Fur-
ther investigations with a larger sample are needed.
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